One Stop Solution For In-Depth Market Research Reports

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Analyzers, Service), Application (Respiratory Diseases, HAIs, STDs, Cancer, Hepatitis), Technology (RT-PCR, INAAT), End User (Physician Office, Hospitals, ICUs) - Global Forecast to 2026


Product Code : MNMHC00109796
Survey : MarketsandMarkets
Publish On : 20, May, 2022
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

"The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period. Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics and increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests. On the other hand, stringent and time-consuming regulatory policies that significantly increase the product launch cycle may challenge market growth post their commercialization.

“The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period”
The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services. The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2020. The requirement assays & kits in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of assays & kits compared to instruments. 

“Sexually transmitted diseases segment accounted for the highest CAGR”
Based on applications, the point-of-care molecular diagnostics market is segmented into respiratory diseases, sexually transmitted diseases, hospital-acquired infections, cancer, hepatitis, gastrointestinal disorders, and other applications. In 2020, the sexually transmitted diseases segment accounted for the highest growth rate. The increasing prevalence of CT/NG infections, HPV, HIV, and Trichomonas vaginalis and technological advancements are major factors driving the growth of this market segment.

“Hospitals & ICUs segment accounted for the highest CAGR”
Based on end users, the market is segmented into physicians’ offices, hospitals & ICUs, research institutes, and other end users. In 2020, the hospitals & ICUs segment accounted for the highest growth rate. This can be attributed to the increasing number of hospitals and high demand for diagnostic products in hospitals.

“North America: The fastest-growing region point-of-care molecular diagnostics market”
The global point-of-care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America accounted for the largest share of the global point-of-care molecular diagnostics market. Factors such as the highly developed healthcare system in the US and Canada and the easy accessibility to technologically advanced instruments are driving the growth of the point-of-care molecular diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:

•    By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
•    By Designation: C-level - 27%, D-level - 18%, and Others - 55%
•    By Region: North America - 51%, Europe - 21%, Asia Pacific - 18% and the Rest of the World – 10%

Lits of Companies Profiled in the Report:
•    Abbott Laboratories (US)
•    F. Hoffmann-La Roche Ltd. (Switzerland)
•    bioMérieux SA (France)
•    Danaher Corporation (US)
•    Quidel Corporation (US)
•    QIAGEN N.V. (Netherlands)
•    Co-Diagnostics, Inc. (US)
•    Biocartis NV (Belgium)
•    Meridian Bioscience, Inc. (US)
•    Thermo Fisher Scientific, Inc. (US)
•    Lucira Health, Inc. (US)
•    Cue Health (US)
•    OpGen, Inc. (US)
•    Binx Health, Inc. (US)
•    Molbio Diagnostics Pct. Ltd. (India)
•    Genomadix (Canada)
•    Visby Medical, Inc. (US)
•    QuikPath PTE Ltd. (Singapore)
•    MD-Bio (US)
•    QuantuMDx Group Ltd. (UK)
•    Aidian Oy (Finland)
•    GeneSTAT Molecular Diagnostics, LLC (US).

Research Coverage:
This report provides a detailed picture of the global point-of-care molecular diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall point-of-care molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities."

TABLE OF CONTENTS

1    INTRODUCTION    34
1.1    OBJECTIVES OF THE STUDY    34
1.2    MARKET DEFINITION    34
1.2.1    INCLUSIONS AND EXCLUSIONS OF THE STUDY    35
1.2.2    MARKETS COVERED    35
FIGURE 1    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION    35
1.2.3    YEARS CONSIDERED FOR THE STUDY    36
1.3    CURRENCY    36
1.4    LIMITATIONS    36
1.5    STAKEHOLDERS    37
1.6    SUMMARY OF CHANGES    37
2    RESEARCH METHODOLOGY    38
2.1    RESEARCH DATA    38
2.2    RESEARCH APPROACH    38
FIGURE 2    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN    38
2.2.1    SECONDARY DATA    39
2.2.1.1    Key data from secondary sources    39
2.2.2    PRIMARY DATA    40
2.2.2.1    Primary sources    41
2.2.2.2    Key data from primary sources    41
2.2.2.3    Key industry insights    42
2.2.2.4    Breakdown of primary interviews    42
FIGURE 3    BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS    42
FIGURE 4    BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION    43
2.3    MARKET SIZE ESTIMATION    43
2.3.1    BOTTOM-UP APPROACH    44
2.3.1.1    Approach 1: Company revenue estimation approach    44
FIGURE 5    BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH    44
2.3.1.2    Approach 2: Market estimation from the parent market    44
FIGURE 6    BOTTOM-UP APPROACH: MARKET ESTIMATION FROM THE PARENT MARKET    44
2.3.1.3    Approach 3: Presentations of companies and primary interviews    45
2.3.1.4    Growth forecast    45
2.3.1.5    CAGR projections    45
FIGURE 7    CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS    45
2.3.2    TOP-DOWN APPROACH    46
FIGURE 8    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH    46
2.4    MARKET BREAKDOWN & DATA TRIANGULATION    47
FIGURE 9    DATA TRIANGULATION METHODOLOGY    47
2.5    MARKET SHARE ANALYSIS    48
2.6    ASSUMPTIONS FOR THE STUDY    48
2.7    RISK ASSESSMENT    49
2.7.1    RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET    49
2.8    GROWTH RATE ASSUMPTIONS    49
2.9    COVID-19 HEALTH ASSESSMENT    49
2.10    COVID-19 ECONOMIC ASSESSMENT    49
2.11    ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO    50
FIGURE 10    CRITERIA IMPACTING THE GLOBAL ECONOMY    50
FIGURE 11    RECOVERY SCENARIO OF THE GLOBAL ECONOMY    51
2.12    ASSESSMENT OF THE IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET    52
3    EXECUTIVE SUMMARY    53
FIGURE 12    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)    53
FIGURE 13    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)    54
FIGURE 14    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 
2021 VS. 2026 (USD MILLION)    55
FIGURE 15    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 
2021 VS. 2026 (USD MILLION)    56
FIGURE 16    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 
2021 VS. 2026 (USD MILLION)    56
4    PREMIUM INSIGHTS    58
4.1    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW    58
FIGURE 17    RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD    58
4.2    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026    59
FIGURE 18    ASSAYS & KITS SEGMENT WILL CONTINUE TO DOMINATE 
THE MARKET IN 2026    59
4.3    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 
2021 VS. 2026    59
FIGURE 19    RT-PCR SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026    59
4.4    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 
2021 VS. 2026    60
FIGURE 20    RESPIRATORY DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD    60
4.5    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 
2021 VS. 2026    60
FIGURE 21    PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE 
THE MARKET IN 2026    60
4.6    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES    61
FIGURE 22    ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD    61
5    MARKET OVERVIEW    62
5.1    INTRODUCTION    62
5.2    MARKET DYNAMICS    62
FIGURE 23    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    62
5.2.1    DRIVERS    63
5.2.1.1    Increasing prevalence of infectious diseases and cancer    63
5.2.1.2    Rising focus on decentralized diagnostics and increasing 
R&D funding    63
5.2.1.3    Increasing awareness on the early detection of infectious diseases    64
5.2.1.4    Increasing use of POC diagnostic tests    64
5.2.2    RESTRAINTS    65
5.2.2.1    Unfavorable reimbursement scenario    65
5.2.2.2    High capital investments and low cost-benefit ratio    65
5.2.3    OPPORTUNITIES    66
5.2.3.1    Growing R&D activities in point-of-care molecular diagnostics testing    66
5.2.3.2    Growth opportunities in emerging countries    66
5.2.4    CHALLENGES    67
5.2.4.1    Stringent and time-consuming regulatory policies that significantly increase the product launch cycle    67
5.2.4.2    Introduction of alternative technologies    67
5.3    IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET    68
5.4    PRICING ANALYSIS    69
TABLE 1    PRICES OF POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS (2021)    69
5.5    PATENT ANALYSIS    70
5.6    TRADE ANALYSIS    70
5.6.1    TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS    70
TABLE 2    IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)    70
TABLE 3    EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)    71
5.7    VALUE CHAIN ANALYSIS    71
FIGURE 24    MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES    71
5.8    SUPPLY CHAIN ANALYSIS    72
FIGURE 25    DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES    73
5.9    ECOSYSTEM ANALYSIS    73
FIGURE 26    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS    73
5.9.1    ROLE IN THE ECOSYSTEM    74
5.10    PORTER’S FIVE FORCES ANALYSIS    75
TABLE 4    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS    75
5.10.1    THREAT FROM NEW ENTRANTS    75
5.10.2    THREAT FROM SUBSTITUTES    75
5.10.3    BARGAINING POWER OF BUYERS    75
5.10.4    BARGAINING POWER OF SUPPLIERS    75
5.10.5    DEGREE OF COMPETITION    76
5.11    PESTLE ANALYSIS    76
5.12    REGULATORY LANDSCAPE    77
5.12.1    NORTH AMERICA    77
5.12.1.1    US    77
5.12.1.2    CANADA    77
5.12.2    EUROPE    77
5.12.3    ASIA PACIFIC    78
5.12.3.1    Japan    78
5.12.3.2    India    78
5.12.3.3    China    78
5.12.4    LATIN AMERICA    78
5.12.4.1    Brazil    79
5.12.4.2    Mexico    79
5.12.5    MIDDLE EAST    79
5.12.6    AFRICA    79
5.13    TECHNOLOGY ANALYSIS    79
5.14    DISRUPTIVE TECHNOLOGIES IN THE POINT-OF-CARE MOLECULAR 
DIAGNOSTICS MARKET    80
5.14.1    REVENUE SHIFT AND REVENUE POCKETS FOR THE POC MOLECULAR DIAGNOSTICS MARKET    80
FIGURE 27    REVENUE SHIFT FOR THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET    80
6    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE    81
6.1    INTRODUCTION    82
TABLE 5    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    82
TABLE 6    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    82
6.2    ASSAYS & KITS    82
6.2.1    RECURRENT PURCHASE OF ASSAYS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH    82
TABLE 7    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2018–2020 (USD MILLION)    83
TABLE 8    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, 
BY REGION, 2021–2026 (USD MILLION)    83
6.3    INSTRUMENTS & ANALYZERS    84
6.3.1    INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET SEGMENT    84
TABLE 9    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2018–2020 (USD MILLION)    84
TABLE 10    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2026 (USD MILLION)    85
6.4    SOFTWARE & SERVICES    85
6.4.1    GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN THIS MARKET SEGMENT    85
TABLE 11    POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
 BY REGION, 2018–2020 (USD MILLION)    86
TABLE 12    POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, 
BY REGION, 2021–2026 (USD MILLION)    86
7    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY    87
7.1    INTRODUCTION    88
TABLE 13    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)    88
TABLE 14    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)    88
7.2    RT-PCR    88
7.2.1    GROWING USE OF RT-PCR IN COVID-19 TESTING IS A MAJOR DRIVER FOR THIS SEGMENT    88
TABLE 15    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, 
BY REGION, 2018–2020 (USD MILLION)    89
TABLE 16    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, 
BY REGION, 2021–2026 (USD MILLION)    89
7.3    INAAT    90
7.3.1    COST BENEFITS OF INAAT ARE A KEY FACTOR DRIVING MARKET GROWTH    90
TABLE 17    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2018–2020 (USD MILLION)    90
TABLE 18    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2026 (USD MILLION)    91
7.4    OTHER TECHNOLOGIES    91
TABLE 19    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2020 (USD MILLION)    91
TABLE 20    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION)    92
8    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION    93
8.1    INTRODUCTION    94
TABLE 21    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)    94
TABLE 22    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)    94
8.2    RESPIRATORY DISEASES    95
8.2.1    GROWING PREVALENCE OF COVID-19 TO DRIVE GROWTH IN 
THIS MARKET SEGMENT    95
TABLE 23    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018–2020 (USD MILLION)    96
TABLE 24    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2026 (USD MILLION)    96
8.3    SEXUALLY TRANSMITTED DISEASES    96
8.3.1    TECHNOLOGICAL ADVANCEMENTS FOR THE DETECTION OF STDS PLAY A MAJOR ROLE IN DRIVING THE GROWTH OF THIS MARKET    96
TABLE 25    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018–2020 (USD MILLION)    97
TABLE 26    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2026 (USD MILLION)    97
8.4    HOSPITAL-ACQUIRED INFECTIONS    98
8.4.1    RISING BURDEN OF MRSA WILL DRIVE THE GROWTH OF THE MARKET IN THE COMING YEARS    98
TABLE 27    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2018–2020 (USD MILLION)    98
TABLE 28    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2026 (USD MILLION)    99
8.5    CANCER    99
8.5.1    RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET GROWTH    99
TABLE 29    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, 
BY REGION, 2018–2020 (USD MILLION)    100
TABLE 30    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, 
BY REGION, 2021–2026 (USD MILLION)    100
8.6    HEPATITIS    101
8.6.1    INCREASE IN CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO DRIVE MARKET GROWTH    101
TABLE 31    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, 
BY REGION, 2018–2020 (USD MILLION)    101
TABLE 32    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, 
BY REGION, 2021–2026 (USD MILLION)    102
8.7    GASTROINTESTINAL DISORDERS    102
8.7.1    INCREASE CASES OF GASTROINTESTINAL DISORDERS 
TO DRIVE MARKET GROWTH    102
TABLE 33    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2018–2020 (USD MILLION)    102
TABLE 34    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2026 (USD MILLION)    103
8.8    OTHER APPLICATIONS    103
TABLE 35    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2020 (USD MILLION)    103
TABLE 36    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2026 (USD MILLION)    104
9    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER    105
9.1    INTRODUCTION    106
TABLE 37    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 
2018–2020 (USD MILLION)    106
TABLE 38    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 
2021–2026 (USD MILLION)    106
9.2    PHYSICIANS’ OFFICES    107
9.2.1    EARLY RESULTS OF POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH IN THIS MARKET    107
TABLE 39    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2018–2020 (USD MILLION)    107
TABLE 40    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2026 (USD MILLION)    107
9.3    HOSPITALS & ICUS    108
TABLE 41    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2018–2020 (USD MILLION)    108
TABLE 42    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2026 (USD MILLION)    109
TABLE 43    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2018–2020 (USD MILLION)    109
TABLE 44    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2026 (USD MILLION)    109
9.3.1    SEPSIS    110
9.3.1.1    Growing need for quick diagnosis and treatment will drive growth in this market    110
TABLE 45    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, 
BY REGION, 2018–2020 (USD MILLION)    110
TABLE 46    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, 
BY REGION, 2021–2026 (USD MILLION)    110
9.3.2    GASTROENTERITIS    111
9.3.2.1    Increasing number of gastroenteritis cases in hospital emergency departments to propel growth in this market    111
TABLE 47    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2018–2020 (USD MILLION)    111
TABLE 48    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2021–2026 (USD MILLION)    111
9.3.3    MENINGOENCEPHALITIS    112
9.3.3.1    Severity of the disease and the need for early disease diagnosis to drive market growth    112
TABLE 49    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2018–2020 (USD MILLION)    112
TABLE 50    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2021–2026 (USD MILLION)    112
9.3.4    OTHER DISEASES    113
TABLE 51    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2018–2020 (USD MILLION)    113
TABLE 52    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2021–2026 (USD MILLION)    113
9.4    RESEARCH INSTITUTES    114
9.4.1    INCREASING USE OF POC MOLECULAR DIAGNOSTICS TESTS IN GENOMICS RESEARCH WILL DRIVE THIS MARKET SEGMENT    114
TABLE 53    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2018–2020 (USD MILLION)    114
TABLE 54    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2026 (USD MILLION)    114
9.5    OTHER END USERS    115
TABLE 55    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2020 (USD MILLION)    115
TABLE 56    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)    115
10    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION    116
10.1    INTRODUCTION    117
TABLE 57    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 
2018–2020 (USD MILLION)    117
TABLE 58    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 
2021–2026 (USD MILLION)    117
10.2    NORTH AMERICA    117
FIGURE 28    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT    118
TABLE 59    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY COUNTRY, 2018–2020 (USD MILLION)    119
TABLE 60    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY COUNTRY, 2021–2026 (USD MILLION)    119
TABLE 61    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    119
TABLE 62    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    120
TABLE 63    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    120
TABLE 64    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    120
TABLE 65    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    121
TABLE 66    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    121
TABLE 67    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION)    122
TABLE 68    NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION)    122
10.2.1    US    122
10.2.1.1    Increasing prevalence of infectious diseases—a key factor driving market growth in the US    122
TABLE 69    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    123
TABLE 70    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    123
TABLE 71    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)    124
TABLE 72    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)    124
TABLE 73    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)    124
TABLE 74    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)    125
TABLE 75    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    125
TABLE 76    US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    126
10.2.2    CANADA    126
10.2.2.1    Rising patient population in Canada to drive market growth in the coming years    126
TABLE 77    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    126
TABLE 78    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    127
TABLE 79    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    127
TABLE 80    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    127
TABLE 81    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    128
TABLE 82    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    128
TABLE 83    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION)    129
TABLE 84    CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION)    129
10.3    EUROPE    129
TABLE 85    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION)    130
TABLE 86    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)    130
TABLE 87    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    131
TABLE 88    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    131
TABLE 89    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    131
TABLE 90    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    132
TABLE 91    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    132
TABLE 92    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    133
TABLE 93    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION)    133
TABLE 94    EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION)    134
10.3.1    GERMANY    134
10.3.1.1    Increasing healthcare expenditure to drive market growth in Germany    134
TABLE 95    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    135
TABLE 96    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    135
TABLE 97    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    135
TABLE 98    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    136
TABLE 99    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    136
TABLE 100    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    137
TABLE 101    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION)    137
TABLE 102    GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION)    138
10.3.2    FRANCE    138
10.3.2.1    Rising R&D expenditure in France to drive market growth    138
TABLE 103    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    138
TABLE 104    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    139
TABLE 105    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    139
TABLE 106    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    139
TABLE 107    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    140
TABLE 108    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY APPLICATION, 2021–2026 (USD MILLION)    140
TABLE 109    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY END USER, 2018–2020 (USD MILLION)    141
TABLE 110    FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY END USER, 2021–2026 (USD MILLION)    141
10.3.3    ITALY    141
10.3.3.1    Adoption of advanced diagnostic technologies to drive market growth in Italy    141
TABLE 111    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    142
TABLE 112    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    142
TABLE 113    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY TECHNOLOGY, 2018–2020 (USD MILLION)    142
TABLE 114    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    143
TABLE 115    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    143
TABLE 116    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    144
TABLE 117    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    144
TABLE 118    ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    145
10.3.4    UK    145
10.3.4.1    Increasing prevalence of infectious diseases to drive market growth in the UK    145
TABLE 119    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    146
TABLE 120    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    146
TABLE 121    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)    146
TABLE 122    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)    147
TABLE 123    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)    147
TABLE 124    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)    148
TABLE 125    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    148
TABLE 126    UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    149
10.3.5    REST OF EUROPE    149
TABLE 127    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    149
TABLE 128    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    150
TABLE 129    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)    150
TABLE 130    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)    150
TABLE 131    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)    151
TABLE 132    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)    151
TABLE 133    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    152
TABLE 134    ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    152

10.4    ASIA PACIFIC    152
FIGURE 29    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT    153
TABLE 135    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION)    154
TABLE 136    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)    154
TABLE 137    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    154
TABLE 138    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    155
TABLE 139    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    155
TABLE 140    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    155
TABLE 141    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    156
TABLE 142    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    156
TABLE 143    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    157
TABLE 144    APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    157
10.4.1    CHINA    157
10.4.1.1    Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth    157
TABLE 145    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    158
TABLE 146    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    158
TABLE 147    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    158
TABLE 148    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    159
TABLE 149    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    159
TABLE 150    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    160
TABLE 151    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    160
TABLE 152    CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    161
10.4.2    JAPAN    161
10.4.2.1    Universal healthcare reimbursement policy to drive market growth in Japan    161
TABLE 153    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    162
TABLE 154    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    162
TABLE 155    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    162
TABLE 156    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    163
TABLE 157    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    163
TABLE 158    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    164
TABLE 159    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    164
TABLE 160    JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    165
10.4.3    INDIA    165
10.4.3.1    Increasing private & public investments in the country’s healthcare system will drive market growth    165
TABLE 161    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    166
TABLE 162    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    166
TABLE 163    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    166
TABLE 164    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION)    167
TABLE 165    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION)    167
TABLE 166    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION)    168
TABLE 167    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    168
TABLE 168    INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    169
10.4.4    REST OF ASIA PACIFIC (ROAPAC)    169
TABLE 169    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    169
TABLE 170    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    170
TABLE 171    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION)    170
TABLE 172    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY TECHNOLOGY, 2021–2026 (USD MILLION)    170
TABLE 173    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY APPLICATION, 2018–2020 (USD MILLION)    171
TABLE 174    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY APPLICATION, 2021–2026 (USD MILLION)    171
TABLE 175    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION)    172
TABLE 176    ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION)    172

10.5    REST OF THE WORLD    172
TABLE 177    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)    173
TABLE 178    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)    173
TABLE 179    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)    174
TABLE 180    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)    174
TABLE 181    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)    174
TABLE 182    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)    175
TABLE 183    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)    175
TABLE 184    ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)    175
11    COMPETITIVE LANDSCAPE    176
11.1    OVERVIEW    176
11.2    KEY PLAYER STRATEGIES/RIGHT TO WIN    176
11.2.1    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET    177
TABLE 185    STRATEGIES ADOPTED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES    177
11.3    REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS    178
FIGURE 30    REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2015–2020)    178
11.4    MARKET SHARE ANALYSIS    179
TABLE 186    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION    179
11.5    COMPANY EVALUATION QUADRANT    180
11.5.1    STARS    180
11.5.2    EMERGING LEADERS    180
11.5.3    PERVASIVE PLAYERS    180
11.5.4    PARTICIPANTS    181
FIGURE 32    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020    181
11.6    COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)    182
11.6.1    PROGRESSIVE COMPANIES    182
11.6.2    STARTING BLOCKS    182
11.6.3    RESPONSIVE COMPANIES    182
11.6.4    DYNAMIC COMPANIES    182
FIGURE 33    POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020    183

11.7    COMPETITIVE BENCHMARKING    183
FIGURE 34    PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET    183
TABLE 187    COMPANY PRODUCT FOOTPRINT    184
TABLE 188    COMPANY REGIONAL FOOTPRINT    184
11.8    COMPETITIVE SCENARIO    185
11.8.1    PRODUCT LAUNCHES & APPROVALS    185
TABLE 189    KEY PRODUCT LAUNCHES & APPROVALS    185
11.8.2    DEALS    185
TABLE 190    KEY DEALS    185

12    COMPANY PROFILES    187
12.1    KEY PLAYERS    187
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1    ABBOTT LABORATORIES    187
TABLE 191    ABBOTT LABORATORIES: BUSINESS OVERVIEW    187
FIGURE 35    ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)    188
12.1.2    F. HOFFMANN-LA ROCHE LTD.    190
TABLE 192    F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW    190
FIGURE 36    F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)    191
12.1.3    BIOMÉRIEUX SA    193
TABLE 193    BIOMÉRIEUX SA: BUSINESS OVERVIEW    193
FIGURE 37    BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)    194
12.1.4    DANAHER CORPORATION    197
TABLE 194    DANAHER CORPORATION: BUSINESS OVERVIEW    197
FIGURE 38    DANAHER CORPORATION: COMPANY SNAPSHOT (2020)    198
12.1.5    QUIDEL CORPORATION    200
TABLE 195    QUIDEL CORPORATION: BUSINESS OVERVIEW    200
FIGURE 39    QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)    201
12.1.6    QIAGEN N.V.    204
TABLE 196    QIAGEN N.V.: BUSINESS OVERVIEW    204
FIGURE 40    QIAGEN N.V.: COMPANY SNAPSHOT (2020)    205
12.1.7    CO-DIAGNOSTICS, INC.    207
TABLE 197    CO-DIAGNOSTICS, INC.: BUSINESS OVERVIEW    207
FIGURE 41    CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020)    208
12.1.8    BIOCARTIS NV    211
TABLE 198    BIOCARTIS NV: BUSINESS OVERVIEW    211
FIGURE 42    BIOCARTIS NV: COMPANY SNAPSHOT (2020)    212
12.1.9    MERIDIAN BIOSCIENCE, INC.    215
TABLE 199    MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW    215
FIGURE 43    MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2020)    216
12.1.10    THERMO FISHER SCIENTIFIC INC.    218
TABLE 200    THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW    218
FIGURE 44    THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)    219
12.2    OTHER PLAYERS    221
12.2.1    LUCIRA HEALTH, INC.    221
12.2.2    CUE HEALTH    221
12.2.3    OPGEN, INC.    222
12.2.4    BINX HEALTH, INC.    222
12.2.5    MOLBIO DIAGNOSTICS PVT. LTD.    223
12.2.6    GENOMADIX    224
12.2.7    VISBY MEDICAL, INC.    224
12.2.8    QUIKPATH PTE. LTD.    224
12.2.9    MD-BIO    225
12.2.10    QUANTUMDX GROUP LTD.    225
12.2.11    AIDIAN OY    226
12.2.12    GENESTAT MOLECULAR DIAGNOSTICS, LLC    226
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13    APPENDIX    227
13.1    DISCUSSION GUIDE    227
13.2    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    230
13.3    AVAILABLE CUSTOMIZATIONS    232
13.4    RELATED REPORTS    232
13.5    AUTHOR DETAILS    233

Shibuya data count

Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.

Recommended reports

+